Industry news, page-1885

the strategy for AML is ultimately to have a low-intensity combo with Decitabine @Bluegumnuts .

The game plan would be to license / partner with Astex so it’s more competitive against Venetoclax. It’s already known that Bisantrene synergises with both Venetoclax and Decitabine. There are a number of head to head trials where Decitabine trumps Venetoclax. Also, Venetoclax is ineffective with Extramedullary AML.

We already have a drug supply agreement with Astex for Decitabine. The bigger play is solid tumour combo with Decitabine and Bisantrene. Decitabine is only effective for blood cancers but in combo with Bisantrene, Decitabine has been shown to be effective anti-cancer in solid tumours.

The above is independent of the cardio protect strategy as Decitabine is generally heart safe. That said, Venetoclax is cardiotoxic and again limited to AML as a BCL2 inhibitor.

The upcoming trial is looking to test the above in the clinic. Some great readings on the above in ASH publications independent studies and RAC preclinicals.

R/R AML and EMD AML or cardiac risk patients seems to be unmet clinical needs where Bisantrene performs well against SoC.

Hopefully this gives you some insight which is not very obvious. Enjoy!